(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Audits of the Top Science fiction Movies This Year - 2Picking Your Next SUV: 4 Brands Offering Execution, Solace, and Wellbeing
- 3Travels to Dream Objections in Europe
- 4Twelve injured near Beit Shemesh, reports of shrapnel impact in Eilat as Iran targets Israel
- 5RFK Jr. says he's following 'gold standard' science. Here's what to know
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- Fundamental Home Machines: An Easy to understand Determination Guide
- Europe: 4 Urban communities for a Paramount Social Experience
- Mexico says a third of 130,000 missing people might be alive, fueling criticisms by families
- Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- Obamacare enrollment declines as US subsidies expire
- Dwayne ‘the Rock’ Johnson opens up about being the 'new guy' again — and why this moment feels like a new life
- Survey: Canteen Cups With Great Warm Protection Impact
- Why screening for the deadliest cancer in the U.S. misses most cases
